Preliminary results within two hours.. A genomic test speeds up the diagnosis of brain tumors in Britain

Preliminary results within two hours.. A genomic test speeds up the diagnosis of brain tumors in Britain
While the patient lay inside the operating room at a university hospital in the British city of Nottingham, a small sample of the tumor extracted from his brain was going through a different path in a nearby laboratory. Within about 20 minutes, the DNA of the sample was analyzed, and after less than two hours, preliminary information reached the surgical team to help it understand the nature of the infection. Brain tumors Which he deals with before the end of the process.
This experience has become part of a broader trend within… British National Health Service (NHS), which has begun expanding the use of a rapid genomic test developed by researchers and clinicians at the University of Nottingham and its university hospitals. The goal is to reduce the diagnostic journey that used to extend for weeks to days, with the possibility of obtaining a preliminary classification of the tumor during surgery in some cases.
The result that appears within two hours does not mean that the final diagnosis is complete; It provides a preliminary indication of the type of tumor, while a more detailed molecular diagnosis requires additional analyzes that may take several days.
Why does diagnosis take time?
Diagnosis Brain tumors It is a complex process because doctors deal with more than 100 different types, which vary in their speed of growth and how they respond to treatment.
The journey usually begins with imaging tests, such as an MRI or CT scan, and then doctors obtain a sample of the tumor through a biopsy — a medical procedure in which a small piece of tissue is removed for examination in the laboratory — or during surgery. The tissues are then transferred to the pathology laboratory to conduct a series of tests that help determine the type of tumor and its characteristics. The complete path may extend for weeks, while the patient and his family wait for an answer that determines the next step.
The importance of shortening this time increases as approximately 13,000 cases of primary brain tumors are recorded annually in the United Kingdom, while these tumors represent one of the leading causes of cancer death among children and adults under the age of forty.

What does the test read?
Instead of relying solely on the appearance of brain tumor cells, the new test looks at the DNA in the sample. Cancer cells carry genetic characteristics and changes that can help doctors classify the tumor more accurately. The test reads this information to get an early indication of the type Brain tumorsThen, analyzes are completed to reach a more detailed molecular diagnosis within days.
The process can be simplified in a short path:
- A sample of the tumor is taken during a biopsy or surgery.
- The genetic material within the sample is analysed.
- Genetic characteristics help give a preliminary classification of the tumor.
- Additional analyzes are continued to reach a more detailed diagnosis.
Thus, genetic information moves from the laboratory to a practical part of medical decision-making.
Two hours in the operating room
The potential of the technology was clearly demonstrated in a recent operation at Nottingham University Hospitals, where a sample of the tumor was taken during surgery and transferred to a laboratory within the hospital, and it took about 20 minutes to read the genetic sequence. Less than two hours after the sample arrived at the laboratory, the surgical team received initial information while the operation was still ongoing.
Here speed becomes more than just reducing the waiting period. In surgeries Brain tumors In cases where the exact type of tumor was not known before the operation, the initial classification can add new information to the surgeon when considering how much tumor can be removed while preserving as much healthy brain tissue as possible.
The surgical decision remains based on a combination of medical data, the patient's condition, and the location of the tumor, while genomic testing provides an additional element that helps the team build a clearer picture.

From diagnosis to treatment
After surgery is completed, the importance of analysis continues Brain tumors Genetically; Because determining the type and molecular characteristics may affect the choice of treatment path, including chemotherapy or radiation therapy when needed.
Access to this information early may help initiate appropriate treatment more quickly, and may also open the way for some patients to enroll in clinical trials that require specific genetic characteristics in the tumor.
Is the value of medical diagnosis measured by accuracy alone? For a patient waiting to learn the nature of the tumor and the course of treatment, time itself becomes part of the quality of care. Hence, the project meets the third goal of sustainable development, concerned with good health and well-being, by using innovation to reduce waiting times and support early access to appropriate treatment.
To learn how other technologies are using medical data to improve cancer management, read also: Artificial intelligence predicts breast cancer…a new technology that outperforms traditional methods.
Five centers start the application
NHS England is investing more than £2 million over two years in a dedicated genomics and brain cancer network, paving the way for expanding the use of the test.
The first phase begins within five centers affiliated with the Authority:
- University Hospitals Birmingham.
- Nottingham University Hospitals.
- Great Ormond Street Hospital for Children.
- King's College Hospital.
- Newcastle Hospitals.
The network is later set to expand to include genomic laboratories in Bristol, Oxford, Leeds and Manchester.
The program aims to build a standardized method through which brain surgeons, pathology services and genomic medicine specialists can be connected, while gathering sufficient evidence on the performance of the technology before expanding its use across the health system.
Building a network for genomic diagnosis
This move reveals another aspect of medical innovation; The success of the technology within one laboratory alone does not guarantee that its benefit will reach a larger number of patients. What is also required is a network of laboratories, surgical staff, and specialists capable of using the results within an integrated treatment course.
In this sense, it serves Sustainable Development Goal 9, linked to innovation and infrastructureThe goal goes beyond developing a new test to building a system capable of applying it and providing its results in a consistent manner within hospitals.
Expanding testing is also consistent with England's National Cancer Plan, which prioritizes research, innovation and expansion of genomic testing, early diagnosis and treatment.
Ultimately, the value of testing lies in the potential to provide information that becomes available during this time. The surgeon may obtain an initial classification during the procedure, and the doctor can move on to a more detailed diagnosis within days, while the patient may have quicker access to a treatment or a clinical trial that matches the genetic characteristics of his tumor.
Here you look The Earth Guards Foundation To speed up diagnosis Brain tumors As an example of how scientific innovation moves from the laboratory to tangible impact within healthcare; The more accurate knowledge becomes available in a timely manner, the greater the ability of doctors to make more informed decisions, and the patient shortens part of the waiting journey between suspecting the disease and starting to treat it.




